Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreDrug targets and modes of action remain two of the biggest challenges in modern drug discovery and development. At Alfa Cytology, we have established a comprehensive platform to support the target validation of bladder cancer targets in different therapeutic areas.
Target identification (identifying the correct drug target for a disease) and target validation (demonstrating the effect of target perturbation on disease biomarkers and disease endpoints) are important steps in drug development. Target validation is a critical step in the discovery of new drugs for bladder cancer, and this important process involves the application of a range of techniques to demonstrate that a drug works against its target. The spectrum of target validation techniques is summarized below:
Fig 1. Techniques for target validation.
Early and comprehensive target validation helps to establish a clear link between target manipulation and disease efficacy, thereby significantly increasing the chances of trial success. Once the target reaches an acceptable level of validation and disease association, the programme moves to the hit identification phase.
Relying on high-resolution mass spectrometry platform, combined with affinity chromatography and active-site directed probe technology, Alfa Cytology has developed and validated a variety of small molecule target identification platforms. Our target-based small molecule drug target identification solutions include:
METHODS | DESCRIPTIONS |
---|---|
Microarrays | Allows the simultaneous detection of thousands of genes and provides a snapshot of gene expression patterns within a sample. |
RNA-Seq | Offers a comprehensive and quantitative analysis of the entire transcriptome. |
qPCR | A sensitive and specific method used to quantify the expression of selected genes. |
NanoString Technology | Direct measurement of individual RNA molecules. |
scRNA-Seq | Provides a detailed view of gene expression at the single-cell level. |
At Alfa Cytology, we are dedicated to supporting your bladder cancer research and development needs. Our team of experienced scientists and researchers is ready to assist you in every step of your project, from protocol design to project completion. We offer a wide range of products, services, and solutions that can help accelerate your research and facilitate the validation of targets for bladder cancer. If you have any needs, please contact us today.
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.